Comorbidity Profile of Familial Mediterranean Fever Patients Varies by Treatments

Authors : Esra Kayacan Erdoğan, Hakan Babaoglu, Şerife Coşkun, Rezan Koçak Ulucaköy, Kevser Orhan, Serdar Can Güven, Ebru Atalar, Bahar Özdemir Ulusoy, Hatice Ecem Konak, Pınar Akyüz Dağli, Özlem Karakaş, Hakan Apaydın, Bünyamin Polat, İsmail Doğan, Yüksel Maraş, Ahmet Omma, Orhan Küçükşahin, Şükran Erten, Berkan Armağan

Pages : 53-60

Doi:10.52827/hititmedj.1582847

View : 44 | Download : 21

Publication Date : 2025-02-25

Article Type : Research Paper

Abstract :Objective: Comorbidities may have an impact on the patient’s quality of life and even survival. Treatment resistance in Familial Mediterranean Fever (FMF) may indirectly indicate severe disease, with inflammation-related comorbidities increasing as severity rises. In the literature, there are no sufficient studies regarding comorbidities in FMF patients. In this study, we aimed to evaluate the comorbid conditions of patients according to FMF treatment steps. Material and Method: We retrospectively reviewed 740 patients with FMF treated at our rheumatology clinic between May 2019 and March 2024. Patient characteristics, comorbidities, and FMF treatments of patients were evaluated. Patients were grouped according to their FMF treatment: coated colchicine, compressed colchicine, and IL-1 inhibition. Patients received treatments aligned with their disease activity, in accordance with current reimbursement guidelines. Results: The mean age (SD) of FMF patients was 40.7 (13.3) and 62.4% were female. Of the 44.7% all patients had at least one comorbidity. The three most common comorbidities are hypertension (20%), hyperlipidemia (7%), and depression (6.8%). The initial coated colchicine treatment was changed in a total of 24.5% to compressed colchicine, further step up was done in 13.2% patients to IL-1 inhibition. Hypertension and chronic kidney disease were more common in patients under IL-1 inhibitor treatment. Conclusion: Our retrospective analysis shows that FMF patients, especially those in the IL-1 inhibitor group, frequently experience comorbidities like hypertension, hyperlipidemia, and depression, even though these patients are younger, suggesting a potential link to severe disease. A comprehensive evaluation of comorbidities, especially in severe disease, is essential to prevent complications, and improve quality of life.
Keywords : Ailevi akdeniz ateşi, hipertansiyon, kolşisin, komorbidite

ORIGINAL ARTICLE URL